Explore more about: Computational Modeling

NIBIB has established the Center for Biomedical Engineering Technology Acceleration—BETA Center, a new intramural research program to solve a range of medicine’s most pressing problems. The BETA Center will serve the wider NIH intramural research program as a biotechnology resource and catalyst for NIH research discoveries.

Medical science is a key step closer to the cryopreservation of brain slices used in neurological research, pancreatic cells for the treatment of diabetes and even whole organs thanks to a new computer model that predicts how tissue’s size will change during the preservation process.

NIBIB-funded researchers are working on an ankle prosthetic that relies on the user’s residual muscles—and the electrical signals that they generate—to help amputees control their posture continuously.

A change of instructions in a computer program directs the computer to execute a different command. Similarly, synthetic biologists are learning the rules for how to direct the activities of human cells.

A team of NIH microscopists and computer scientists used a type of artificial intelligence called a neural network to obtain clearer pictures of cells at work even with extremely low, cell-friendly light levels.

A new study lays out a large medical analytics framework that can be used in neuroscience and neurology to study brain connectivity in living organisms.

A new article looks at the use of virtual imaging trials in effective assessment and optimization of CT and radiography acquisitions and analysis tools to help manage the coronavirus disease (COVID-19) pandemic.

To counter drug resistance, scientists must engineer new drugs to kill mutated cancer cells or pathogens. Now, Penn State engineers have developed a new approach for predicting which mutation has expanded the most in a population and should be targeted to design the most effective new drug.

Bioengineers have combined standard microscopy, infrared light, and artificial intelligence to assemble digital biopsies that identify important molecular characteristics of cancer biopsy samples.

Whether it is a drug-resistant strain of bacteria, or cancer cells that no longer react to the drugs intended to kill them, diverse mutations make cells resistant to chemicals, and 'second generation' approaches are needed. Now, a team of engineers may have a way to predict which mutations will occur in people, creating an easier path to create effective pharmaceuticals.